Faeth Therapeutics, Inc. (FTH) - Net Assets
Based on the latest financial reports, Faeth Therapeutics, Inc. (FTH) has net assets worth $191.19 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($205.38 Million) and total liabilities ($14.19 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore FTH current and non-current assets for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $191.19 Million |
| % of Total Assets | 93.09% |
| Annual Growth Rate | N/A |
| 5-Year Change | -87.31% |
| 10-Year Change | N/A |
| Growth Volatility | 344.73 |
Faeth Therapeutics, Inc. - Net Assets Trend (2018–2025)
This chart illustrates how Faeth Therapeutics, Inc.'s net assets have evolved over time, based on quarterly financial data. Check FTH intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Annual Net Assets for Faeth Therapeutics, Inc. (2018–2025)
The table below shows the annual net assets of Faeth Therapeutics, Inc. from 2018 to 2025. For live valuation and market cap data, see Faeth Therapeutics, Inc. (FTH) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $18.59 Million | -51.57% |
| 2024-12-31 | $38.39 Million | -40.85% |
| 2023-12-31 | $64.89 Million | -37.24% |
| 2022-12-31 | $103.41 Million | -29.42% |
| 2021-12-31 | $146.51 Million | +821.87% |
| 2020-12-31 | $15.89 Million | +123.15% |
| 2019-12-31 | $-68.66 Million | -28.39% |
| 2018-12-31 | $-53.48 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Faeth Therapeutics, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 20756500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Comprehensive Income | $1.00K | 0.01% |
| Other Components | $301.73 Million | 1622.89% |
| Total Equity | $18.59 Million | 100.00% |
Faeth Therapeutics, Inc. Competitors by Market Cap
The table below lists competitors of Faeth Therapeutics, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ODDITY Tech Ltd. Class A Ordinary Shares
NASDAQ:ODD
|
$783.83 Million |
|
Rashtriya Chemicals and Fertilizers Limited
NSE:RCF
|
$783.97 Million |
|
Nsfocus Information Technology Co Ltd
SHE:300369
|
$784.07 Million |
|
Lsb Industries Inc
NYSE:LXU
|
$784.67 Million |
|
LIGHTHOUSE PROPERTIES
F:87O
|
$783.67 Million |
|
Navient Corp
NASDAQ:NAVI
|
$783.54 Million |
|
CoAsia Microelectronics
TWO:8096
|
$783.40 Million |
|
IFE Elevators Co Ltd
SHE:002774
|
$783.36 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Faeth Therapeutics, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 38,386,000 to 18,592,000, a change of -19,794,000 (-51.6%).
- Net loss of 21,085,000 reduced equity.
- Share repurchases of 1,000 reduced equity.
- Other comprehensive income increased equity by 14,000.
- Other factors increased equity by 1,278,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-21.09 Million | -113.41% |
| Share Repurchases | $1.00K | -0.01% |
| Other Comprehensive Income | $14.00K | +0.08% |
| Other Changes | $1.28 Million | +6.87% |
| Total Change | $- | -51.57% |
Book Value vs Market Value Analysis
This analysis compares Faeth Therapeutics, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.45x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $-78.05 | $36.16 | x |
| 2019-12-31 | $-2.34 | $36.16 | x |
| 2020-12-31 | $0.52 | $36.16 | x |
| 2021-12-31 | $5.29 | $36.16 | x |
| 2022-12-31 | $3.37 | $36.16 | x |
| 2023-12-31 | $2.32 | $36.16 | x |
| 2024-12-31 | $1.53 | $36.16 | x |
| 2025-12-31 | $14.75 | $36.16 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Faeth Therapeutics, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -113.41%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.23x
- Recent ROE (-113.41%) is below the historical average (-55.39%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-7.69 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-9.87 Million |
| 2020 | -126.47% | 0.00% | 0.00x | 1.35x | $-21.69 Million |
| 2021 | -25.11% | 0.00% | 0.00x | 1.05x | $-51.45 Million |
| 2022 | -46.99% | 0.00% | 0.00x | 1.14x | $-58.93 Million |
| 2023 | -52.55% | 0.00% | 0.00x | 1.15x | $-40.59 Million |
| 2024 | -78.56% | 0.00% | 0.00x | 1.18x | $-34.00 Million |
| 2025 | -113.41% | 0.00% | 0.00x | 1.23x | $-22.94 Million |
Industry Comparison
This section compares Faeth Therapeutics, Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $147,081,944
- Average return on equity (ROE) among peers: -21.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | $191.19 Million | 0.00% | 0.07x | $783.82 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $165.48 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-17.08 Million | 0.00% | 0.00x | $335.61 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $181.82 Million | -56.28% | 0.31x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $-41.16 Million | 0.00% | 0.00x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $35.44 Million | -26.32% | 0.18x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $35.27K | -72.00% | 1.50x | $39.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $71.77 Million | -22.23% | 0.06x | $12.08 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $479.08 Million | -51.18% | 0.13x | $3.66 Billion |
About Faeth Therapeutics, Inc.
Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune chec… Read more